Gynecological Health Company Daye Receives FDA Clearance For Its Nude Tampon

Gynecological health startup Daye, best known for having invented the world’s first cannabidiol (CBD) tampon, has obtained FDA 510(k) clearance for its Nude Tampon ahead of its U.S. launch next month. 

Daye’s Nude Tampon is a game-changer for women, girls and assigned female at birth (AFAB) individuals. It offers them a new level of care during their menstrual cycle. Daye is the only brand to clinically test their tampons with human clinical trials, and its Nude tampon is the only tampon on the market sanitised with gamma irradiation, which adds additional protection for tampon customers against microbial contamination.

It is also 100% organic, made using ethically sourced materials, free of dyes, pesticides and fragrances. It is free of plastic, rayon, chlorine bleach, dioxin, phthalates and fragrances – all of which have been commonly found in mainstream tampons. It is also housed in a sustainable sugarcane applicator and a water-soluble, flushable, ocean-safe wrapper, allowing Daye to reduce non-recyclable plastic waste and promote greener periods.

Daye’s Nude Tampon features an innovative protective sleeve, meaning users do not need to worry about shedding tampon fibers which can cause vaginal infections like thrush and BV. With its organic protective sleeve, the Nude Tampon ensures no bits of your tampon overstay their welcome.

“This achievement marks a pivotal moment in our mission to enhance the health and well-being of women and AFAB individuals. Our Nude Tampon underwent rigorous evaluation before its approval, demonstrating the product’s safety and performance,” said Valentina Milanova, founder and CEO of Daye.

“This milestone validates the extensive research, development, and testing that have gone into creating a product that not only meets the highest medical standards but also addresses the menstrual care needs of people with periods,” Milanova added. “What sets the Nude Tampon apart is our commitment to safety (Daye is certified to GMP and ISO1345, and we sanitise and produce our tampons in clean rooms) and sustainability.

“Next, we will introduce a water-soluble tampon applicator. Daye is also working on a Pain-Relieving Tampon for chronic pelvic pain and on a Diagnostic Tampon to help increase access to at-home vaginal health screenings. These additional tampon variants are based on the foundation that the Nude Tampon provides,” Milanova said.

SourceDaye

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”